Prospects and challenges for prophylactic and therapeutic HIV vaccines

Vaccine

Volumn 21, Issue 7-8, 2003, Pages 616-619

  Klein, Michel ^a,b  

^a SANOFI PASTEUR   (France)

^b CANVAC   (Canada)

Author keywords

HIV vaccines

Indexed keywords

CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; GENE PRODUCTS, ENV; HIV INFECTIONS; HUMANS;

EID: 0037472477     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00568-6     Document Type: Conference Paper

References (32)

1. Esparza J., Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet. 355:2000;2061-2066.
2. Johnson R.P., Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10:1998;436-443.
3. Brander C., Walker B.D. T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr. Opin. Immunol. 11:1999;451-459.
4. Mazzoli S.et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1997;1250-1257.
5. Osterhaus A.D.et al. Vaccination with Rev and Tat against AIDS. Vaccine. 17:1999;2713-2714.
6. Amara R.R.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
7. Hanke T.et al. Effective induction of simiam immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
8. Shiver J.W.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature. 415:2002;331-335.
9. Barouch D.H.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
10. Feinberg M., Moore J. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8:2002;207-210.
11. Mulligan M.J., Weber J. Human trials of HIV-1 vaccines. AIDS. 13(Suppl. A):1999;S105-112.
12. Burton D., Parren P.W.H.I. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat. Med. 6:2000;123-125.
13. Baba T.W.et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
14. Kwong P.D.et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
15. Binley J.M.et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:2000;627-643.
16. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:1998;679-684.
17. Wyatt R.et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:1995;5723-5733.
18. Chan D.C.et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
19. Lehner T.et al. Alloimmunization as a strategy for vaccine design against HIV/AIDS. AIDS Res. Hum. Retrovir. 4:2000;309-313.
20. Ensoli B., Cafaro A. HIV-Tat vaccines. Virus Res. 82:2002;91-101.
21. Robinson H. New hope for an AIDS vaccine. Nat. Rev. 2:2002;239-250.
22. Leung N.J.et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing Gag, Pol, Env, and Nef proteins. Virology. 268:2000;94-103.
23. Gahéry-Ségard H.et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74:2000;1694-1703.
24. Tartaglia J.et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retrovir. 14(Suppl. 3):1998;S291-S298.
25. Hanke T., McMichael A.J. Design and construction of an experimental HIV-1 vaccine for year 2000 clinical trial in Kenya. Nat. Med. 6:2000;951-955.
26. Rosenberg E.S.et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526.
27. Autran B., Carcelain G. Boosting immunity to HIV - can the virus help? Science. 290:2000;946-949.
28. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8324-8326.
29. Ensoli B., Cafaro A. HIV-1 Tat vaccines. Virus Res. 82:2002;91-101.
30. Gringeri A.et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J. Hum. Virol. 1:1998;293-298.
31. Xia J.et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 76:2002;2206-2216.
32. Autran B, personal communication.